Research Analysts Issue Forecasts for BBIO FY2025 Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of BridgeBio Pharma in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will earn ($4.50) per share for the year. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($2.56) per share.

Several other analysts have also commented on the stock. Evercore ISI lifted their price objective on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, December 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $49.00 price target on shares of BridgeBio Pharma in a report on Monday, December 16th. Scotiabank increased their price objective on BridgeBio Pharma from $45.00 to $48.00 and gave the company a “sector outperform” rating in a report on Monday, November 25th. Oppenheimer began coverage on BridgeBio Pharma in a research report on Thursday, October 3rd. They issued a “market perform” rating for the company. Finally, Leerink Partners dropped their price target on BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $48.08.

BridgeBio Pharma Price Performance

NASDAQ BBIO opened at $37.09 on Thursday. The stock has a market capitalization of $7.01 billion, a price-to-earnings ratio of -15.39 and a beta of 1.05. The business’s fifty day moving average is $28.27 and its 200-day moving average is $26.74. BridgeBio Pharma has a one year low of $21.62 and a one year high of $41.04.

Insider Buying and Selling at BridgeBio Pharma

In other BridgeBio Pharma news, CFO Brian C. Stephenson sold 4,156 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total value of $93,135.96. Following the transaction, the chief financial officer now directly owns 93,758 shares in the company, valued at $2,101,116.78. This represents a 4.24 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Neil Kumar sold 27,389 shares of BridgeBio Pharma stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $22.41, for a total value of $613,787.49. Following the sale, the chief executive officer now owns 4,897,443 shares of the company’s stock, valued at approximately $109,751,697.63. This trade represents a 0.56 % decrease in their position. The disclosure for this sale can be found here. Insiders own 24.66% of the company’s stock.

Institutional Trading of BridgeBio Pharma

Institutional investors and hedge funds have recently made changes to their positions in the stock. Values First Advisors Inc. bought a new position in BridgeBio Pharma in the third quarter valued at $57,000. CWM LLC increased its position in shares of BridgeBio Pharma by 132.9% during the 3rd quarter. CWM LLC now owns 3,442 shares of the company’s stock valued at $88,000 after purchasing an additional 1,964 shares during the last quarter. Advisors Asset Management Inc. raised its holdings in shares of BridgeBio Pharma by 56.1% during the 3rd quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company’s stock valued at $117,000 after buying an additional 1,645 shares in the last quarter. Amalgamated Bank lifted its position in BridgeBio Pharma by 24.7% in the 2nd quarter. Amalgamated Bank now owns 4,863 shares of the company’s stock worth $123,000 after buying an additional 962 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in BridgeBio Pharma by 17.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 5,322 shares of the company’s stock valued at $135,000 after acquiring an additional 801 shares during the last quarter. Hedge funds and other institutional investors own 99.85% of the company’s stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.